Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
Adipic acid (PubChem CID: 196)
Celecoxib
Celecoxib (PubChem CID: 2662)
Citric acid (PubChem CID: 311)
Contact angle
Eutectic
Evaporation crystallization
Fumaric acid (PubChem CID: 444972)
Malic acid (PubChem CID: 525)
Nicotinamide (PubChem CID: 936)
Phase diagram
Saccharin (PubChem CID: 5143)
Succinic acid (PubChem CID: 1110)
Tammann’s Triangle
Urea (PubChem CID: 62705)
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
10 Jan 2019
10 Jan 2019
Historique:
received:
25
08
2018
revised:
16
10
2018
accepted:
17
10
2018
pubmed:
23
10
2018
medline:
4
4
2019
entrez:
23
10
2018
Statut:
ppublish
Résumé
Celecoxib (CEL) is a selective cyclooxygenase-2 (COX-2) inhibitor therapeutically indicated for the treatment of rheumatoid arthritis, osteoarthritis, acute pain, and inflammation. However, its poor solubility and dissolution rate significantly hinders its broader application. In this study, eutectic mixtures, as binary pharmaceutical compositions of CEL with adipic acid (ADI) and saccharin (SAC), were identified through a phase diagram and Tammann's triangle intended to improve the wettability and dissolution rate of poorly water-soluble CEL. The contact angles at 0s in the liquid-solid interface were approximately θs (theta) 79.7 ± 0.50° and 86.65 ± 0.45° for CEL-ADI and CEL-SAC, respectively, which were much lower than the value obtained for CEL (92.05 ± 0.75° θ). Moreover, a comparison of the disk intrinsic dissolution rate and powder dissolution properties demonstrated that eutectic mixtures significantly increased the dissolution rate compared with CEL and physical mixtures. A general relationship was elucidated and indicated that the dissolution rate was increased as the contact angle decreased (correlation coefficient, r = 0.9966 ± 0.0031). Therefore, CEL-ADI and CEL-SAC eutectics may offer a novel formulation strategy to enhance the solubility and oral bioavailability of CEL.
Identifiants
pubmed: 30347274
pii: S0378-5173(18)30784-1
doi: 10.1016/j.ijpharm.2018.10.044
pii:
doi:
Substances chimiques
Adipates
0
Cyclooxygenase 2 Inhibitors
0
Excipients
0
adipic acid
76A0JE0FKJ
Saccharin
FST467XS7D
Celecoxib
JCX84Q7J1L
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-71Informations de copyright
Copyright © 2018. Published by Elsevier B.V.